卵巢癌病理组织表达程序性死亡配体1及其对活化T细胞的免疫抑制作用

PD-L1 Expression on Ovarian Cancer and Inhibits the Activated T Cells

目的探讨免疫抑制分子程序性死亡配体1（PD-L1）在卵巢癌病理组织的表达及其生物学功能。方法选择由不同病理类型的卵巢癌肿瘤组织以及正常卵巢组织和卵巢良性腺瘤构建的组织芯片，以兔抗人PD-L1抗体为第1抗体和辣根过氧化物酶标记的抗兔抗体为第2抗体进行免疫组织化学染色，并采用Aperio病理扫描系统结合两位病理科医师进行读片和结果分析。将丝裂霉素预处理的高表达PD—L1的卵巢癌细胞株H08910与PHA活化的T细胞共培养，采用MTT法检测T细胞增殖。结果PD-L1普遍表达于卵巢良性腺瘤和不同病理分级的浆液性囊腺癌、黏液性囊腺癌和内膜样腺癌，而在正常卵巢组织呈弱表达或不表达；以H08910作为细胞模型证实了卵巢癌细胞表达PD-L1可抑制活化T细胞增殖。结论卵巢癌组织普遍表达PD-L1分子并参与肿瘤免疫逃逸，提示了卵巢癌可能适用于靶向PD-L1／PD-1的生物治疗。

Objective To discuss the expression of inhibitory molecule PD-L1 on ovarian cancer and its biological effects. Methods Tissue chip that contains the tissues from ovarian cancer, benign ovarian adenoma and normal ovarian was stained with rabbit anti-human PD-L1 antibody and HRP labeled anti-rabbit antibody. And then the tissue chip was analyzed with Aperio pathological scan system and 2 experienced pathologist. PHA activated T cells were cocultured with ovarian cell line HO8910 that highly expressed PD-L1. T cell proliferation was evaluated with MTT assay. Results PD-L1 was commonly expressed on the ovarian cancer tissue and benign ovarian adenoma, but it was negative or weakly expressed on normal ovarian tissue. HO8910 cell that expresses PD-L1 could inhibit the proliferation of PHA activated T cell. Conclusion PD-L1 expresses on the ovarian cancer tissue and plays an important role in the immune escape of ovarian cancer. It suggests that ovarian cancer is the appropriate candidate of PD-1/PD-L 1 targeting immune therapy.